GLP-1 receptor agonists in the treatment of polycystic ovary syndrome (Q39170244)

9 September 2017

title

GLP-1 receptor agonists in the treatment of polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

9 September 2017

main subject

1 reference

1 reference

Elizabeth Mary Lamos

1 reference

9 September 2017

Rana Malek

series ordinal

1 reference

9 September 2017

Stephen N Davis

series ordinal

1 reference

9 September 2017

language of work or name

English

0 references

publication date

13 February 2017

1 reference

Expert Review of Clinical Pharmacology

9 September 2017

published in

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

401-408

1 reference

The prevalence and features of the polycystic ovary syndrome in an unselected population

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Epidemiology, diagnosis, and management of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Clinical review: Identifying children at risk for polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Polycystic Ovary Syndrome as a Form of FunctionalOvarian Hyperandrogenism Due to Dysregulation ofAndrogen Secretion*

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Effect of lifestyle intervention on the reproductive endocrine profile in women with polycystic ovarian syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Treatment of hirsutism and acne in hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Letrozole versus clomiphene for infertility in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Metabolic actions of insulin in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

Identification and localization of glucagon-like peptide-1 and its receptor in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1292125

10.1080/17512433.2017.1292125

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference